Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Chinese Biotechs Raise $743m In Three March IPOs

Apr 01 2022

• By Dexter Jie Yan

The first biotech IPO on the Beijing Stock Exchange — combined $742.9m in gross proceeds closed out strong March for RemeGen, Recbio and Shouyao • Source: Alamy

Related Content

China’s First ADC Secures Domestic Approval

Jun 10 2021

Hotter Than Oncology? China Immunology Players Raise $650m

Nov 19 2020

Recbio First Biotech To Brave A Hong Kong IPO In 2022

Jan 25 2022

Related Companies

RemeGen Ltd.

Jiangsu Recbio Technology Co., Ltd.

Shouyao Holdings Beijing Co Ltd

Additional Topics

China Asia Pacific Financing ImmunoOncology Vaccines Companies BioPharmaceutical

More from China

More from Focus On Asia

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window